+64.3%
GSK vs VRSN
+54.2%
+10.1%
-28.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | VRSN | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.2% | +1.0% | -2.2% | -1.3% |
| 7D | -1.1% | -1.2% | +0.2% | -0.9% |
| 30D | +7.8% | +3.8% | +4.1% | +7.4% |
| 3M | +0.3% | +9.5% | -9.2% | -0.7% |
| 6M | +3.4% | +10.3% | -6.8% | +2.2% |
| YTD | +5.9% | +30.5% | -24.6% | +2.1% |
| 1Y | +8.2% | +27.9% | -19.7% | +4.7% |
| All | +64.3% | +54.2% | +10.1% | +47.4% |
Cumulative growth
Daily Returns
Daily percentage return beside VRSN.
Daily Out/Under-Performance
Portfolio return minus VRSN return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × VRSN return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded VRSN wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling